Recent advances in endocrine therapy of breast cancer

British Medical Journal

Volumn 315, Issue 7112, 1997, Pages 863-866

  Howell, Anthony ^a   Dowsett, Mitchell ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; DROLOXIFENE; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FORMESTANE; FULVESTRANT; GONADORELIN DERIVATIVE; IDOXIFENE; LETROZOLE; MIPROXIFENE PHOSPHATE; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; VOROZOLE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; DRUG MANUFACTURE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ESTRADIOL BLOOD LEVEL; HORMONAL THERAPY; HUMAN; META ANALYSIS; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; SHORT SURVEY;

EID: 0030930726     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.315.7112.863     Document Type: Short Survey

References (29)

1. Beatson GT. On the treatment of inoperable cases of carinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:104-7.
2. dole MP, Jones CTA, Todd IDH. A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of ICI 146-174, Br J Cancer 197l;25:270-5.
3. Early Breast Cancer Triallists Co-operative Group (EBCTCG). Systemic Treatment of early breast cancer by hormonal, cytotoxic, or immunotheraphy. Lancet 1992;339:1-17,71-85.
4. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985;ii:282.
5. Lippman M, Monaco ME, Bolan G. Effects of oestrone, estradiol and oestriol on hormone responsive human breast cancer in long term tissue culture. Cancer Res 1977;37:1901-7.
6. Miller WR. Endocrine treatment for breast cancers: biological rationale and current progress. J Strroid Biochem Mol Biol 1990;37:467-80.
7. Howell A, DcFriend D, Robertson J, Blamey R, Wallon P. Response to a specific antioestrogen ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995;34:29-30.
8. Chander SK, Newton C, McCague R, Dowsett M, Loqmano Y, Coombes RG. Pyrrolodine-4-iodotamoxifen and 4-iodotanoxifen, new analogues of the antioestrogen tamoxifen for the trreatment of breast cancer. Cancer Res 1991;51:5831-8.
9. Wakeling AE, Dukes M, Bowlet J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-73.
10. De Friend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mausel RE, et al. Investigation of a new pure antioestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994;54:408-14.
11. Ellis PA, Saccani Jotti G, Johnston SRD, E Anderson, A Howell, R A'Herne, et al. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer 1997;72:608-11.
12. Sato M, Glasebrook AL, Bryant HU. Raloxifene: a selective estrogen receptor modulator. J Bone Miner Met 1994;12(suppl 2):S9-20.
13. DeFriend DJ, Anderson E, Bell J, Wilks DP, West CML, Mansel RE, et al. Effects of 4-hydroxytamoxifen and a pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer 1994;70:204-11.
14. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR,Mailliard JA, et al. Randoniscd comparison of tamoxifen and two seprate doses of toremifene in psstmenopausal patients with metastatic breast cancer. J Clin Oncol 1995;13:2556-66.
15. Rausehuing W,Pritchard KI. Droloxifene, a new antioestrogen: its, role in metastatic breast cancer. Breast Cancer Res Treat 1994; 31: 83-94.
16. Tominaga T. Early phase II clinical study of TAT-59 (new antioestrogen in patients with advanced breasl cancer. 19th International Congress of Chemotherapy, Montreal, Canada. 1995.
17. Howell A, DeFriend DJ, Robertson JFR, BIamey RW, Anderson L, Andcrson E, et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific antioestrogen ICI 182780 in woman with advanced breast cancer. Br J Cancer 1996;74:300-8.
18. Schwarzel WC, Kruggel WG, Brodie HJ. Studies on the mechanism of estrogen biosynthesis. VIII. The development of inhibitors of the enzyme system in human placenta. Endocrinology 1973;92:866-80.
19. Buzdar A, Jonat W, Howell A, Jones SE, Bloniqvist C, Vogel CL, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996;14:2000-11.
20. Buzdar A, Jonat W, Howell A, Yin H, Lee D. Significant improved survival with Arimides (anastrozole) versus inegestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials [abstract]. Proc Am Soc Clin Oncol 1997;16:156.
21. Smith I, Dombernowsky P, Falkson G, Leonard. R, Panaseci L, Bellnunt J, et al. Double-blind trial in postmenopausal women with advanced breast cancer showing a dose-effect and superiority of 2.5mg letrzole over megestrol acetate. Eur J Cancer 1996;32A(suppl 2):19.
22. Marty M, Gershanovich M, Campus B, Romien G, Lurie H, Bonaventura T, et al. Letrozole, a new potent, selective aromatase inhibitor superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer previously treated with antioestiogens [abstract]. Proc Am Soc Clin Oncol 1997;16:156.
23. Bergh. J, Bonneterre J, Houston SJ, Uiger HJ, Mnrray R, Nortier J, et al. Vorozole (Rivizor) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing affer tamoxifen [abstract). Proc Am Soc Clin Oncol 1997;16:156.
24. Goss P, Winer E, Tannock I, Schwartz LH, Kremer AB for the North American Vorozole Study Group. Vorozole vs megace in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen [abstract]. Proc Am Soc Clin Oncol 1997;16:155.
25. Dowsett M. Biological background to aromatase inhibition. The Breast 1996;5:196-201.
26. Coombes RC, Hughes SWM, Doesett M. 4-Hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer Eur J Cancer 1992;28A:1941-5.
27. Di Salle E, Ornati C, Paridaens R, Coombes RC, Lobelle JP, Zurlo MG. Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304). In: Motta M, Serio M, eds. Sex hormones and antohormones in endocrine depend pathology: basic clinical aspects. Amsterdam. Elsevier, 1991:303-9.
28. Dowsett M, Vprpbiof DA, Kleeberg UR, Carrion RP, Dodwell DJ, Robertson JFR, et al. A randomized study assessing oestrogen suppression with arimides (anastrozole) and formestane in postmenopausal advanced breast cancer patients. Eur J Cancer 1996;32A(suppl 2):I9.
29. Howell A, Mackintosh J, Jones M, Redford J, Wagstaff J. Sellwoood RA. The definition of the "no charge" category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988;21:1567-72.